| 37.66 0.1 (0.27%) | 12-26 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 46.35 | 1-year : | 49.85 |
| Resists | First : | 39.68 | Second : | 42.68 |
| Pivot price | 36.93 |
|||
| Supports | First : | 34.84 | Second : | 28.99 |
| MAs | MA(5) : | 37.2 |
MA(20) : | 37.24  |
| MA(100) : | 35.65 |
MA(250) : | 0 | |
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 61 |
| RSI | RSI(14): 51.8 |
|||
| 52-week | High : | 63 | Low : | 29.23 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ VCEL ] has closed below upper band by 26.4%. Bollinger Bands are 42.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 3 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 38.15 - 38.29 | 38.29 - 38.41 |
| Low: | 36.78 - 36.95 | 36.95 - 37.11 |
| Close: | 37.39 - 37.63 | 37.63 - 37.85 |
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Wed, 24 Dec 2025
Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Tue, 23 Dec 2025
Discipline and Rules-Based Execution in VCEL Response - Stock Traders Daily
Tue, 23 Dec 2025
How Investors Are Reacting To Vericel (VCEL) Reaffirmed Guidance And MACI-Focused Growth Narrative - Sahm
Sun, 21 Dec 2025
Truist Slashes PT on Vericel Corporation (VCEL) to $45 From $50 - Yahoo Finance
Sun, 21 Dec 2025
Congress Asset Management Co. Lowers Stake in Vericel Corporation $VCEL - MarketBeat
Thu, 18 Dec 2025
Truist Securities Maintains Vericel (VCEL) Buy Recommendation - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 51 (M) |
| Shares Float | 50 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 106.9 (%) |
| Shares Short | 4,200 (K) |
| Shares Short P.Month | 4,440 (K) |
| EPS | 0.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.36 |
| Profit Margin | 5 % |
| Operating Margin | 5.1 % |
| Return on Assets (ttm) | 1 % |
| Return on Equity (ttm) | 4.5 % |
| Qtrly Rev. Growth | 16.6 % |
| Gross Profit (p.s.) | 3.77 |
| Sales Per Share | 5.11 |
| EBITDA (p.s.) | 0.33 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 59 (M) |
| Levered Free Cash Flow | 18 (M) |
| PE Ratio | 144.84 |
| PEG Ratio | 0 |
| Price to Book value | 5.91 |
| Price to Sales | 7.36 |
| Price to Cash Flow | 32.2 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|